Deflazacort

Deflazacort oral suspension is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: Deflazacort oral suspension is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.
Do not take if: Deflazacort oral suspension is contraindicated in patients with known hypersensitivity to deflazacort or to any of the inactive ingredients.
Instances of hypersensitivity, including anaphylaxis, have occurred in patients receiving corticosteroid therapy.

Side effects, and when to stop

The following serious adverse reactions are discussed in more detail in other sections:

Alterations in Endocrine Function
Immunosuppression and Increased Risk of Infection
Alterations in Cardiovascular/Renal Function
Gastrointestinal Perforation
Behavioral and Mood Disturbances
Effects on Bones
Ophthalmic Effects
Immunizations
Serious Skin Rashes
Effects on Growth and Development
Myopathy
Kaposi's Sarcoma
Risk of Serious Adverse Reactions in Infants because of Benzyl Alcohol Preservative
Thromboembolic Events
Anaphylaxis

Who should not take it

Deflazacort oral suspension is contraindicated in patients with known hypersensitivity to deflazacort or to any of the inactive ingredients. Instances of hypersensitivity, including anaphylaxis, have occurred in patients receiving corticosteroid therapy.

Storing it

Store at 20ºC to 25ºC (68ºF to 77ºF); excursions permitted between 15°C to 30°C (59°F to 86°F).

Discard any unused deflazacort oral suspension remaining after 1 month of first opening the bottle.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Deflazacort; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/deflazacort
APA 7th: sofidex. (2026, August 2). Deflazacort. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/deflazacort
AMA 11th: Deflazacort. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/deflazacort

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.